Comparison of clinical outcomes between bioresorbable vascular stents versus conventional drug-eluting and metallic stents: A systematic review and meta-analysis

EuroIntervention

Volumn 12, Issue 2, 2016, Pages e175-e189

  Banach, MacIej ^a   Serban, Maria Corina ^b,c   Sahebkar, Amirhossein ^d,e   García García, Hector M ^f   Mikhailidis, Dimitri P ^g   Martin, Seth S ^h   Brie, Daniel ^c   Rysz, Jacek ^a   Toth, Peter P ^h,i   Jones, Steven R ^h   Hasan, Rani K ^h   Mosteoru, Svetlana ^c   Rifai, Mahmoud Al ^c   Pencina, Michael J ^j   Serruys, Patrick W ^k  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ CGH MEDICAL CENTER   (United States)

^j DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^k IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Absorb BRS; Bioresorbable vascular stents; Drug eluting stents

Indexed keywords

EVEROLIMUS; UMIROLIMUS;

ACUTE CORONARY SYNDROME; ALL CAUSE MORTALITY; ANGINA PECTORIS; BARE METAL STENT; BIOLIMUS ELUTING CORONARY STENT; BIORESORBABLE SCAFFOLD; BIORESORBABLE VASCULAR STENT; CARDIOVASCULAR PARAMETERS; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; CORONARY STENTING; DRUG ELUTING STENT; EVEROLIMUS ELUTING BIORESORBABLE SCAFFOLD; EVEROLIMUS ELUTING CORONARY STENT; FOLLOW UP; HEART DEATH; HEART DISEASE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; META ANALYSIS; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTEMATIC REVIEW; TARGET LESION REVASCULARIZATION; TARGET VESSEL REVASCULARIZATION; ADVERSE EFFECTS; BIODEGRADABLE IMPLANT; CORONARY THROMBOSIS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROCEDURES; TREATMENT OUTCOME;

ABSORBABLE IMPLANTS; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; HUMANS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; TREATMENT OUTCOME;

EID: 84975861186     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Banach M, Serban C, Sahebkar A, Mikhailidis DP, Ursoniu S, Ray KK, Rysz J, Toth PP, Muntner P, Mosteoru S, García-García HM, Hovingh GK, Kastelein JJ, Serruys PW; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology-intravascular ultrasound studies. BMC Med. 2015;13:229.
2. Felix C, Everaert B, Diletti R, Van Mieghem N, Daemen J, Valgimigli M, de Jaegere PP, Zijlstra F, Regar E, Simsek C, Onuma Y, van Geuns RJ. Current status of clinically available bioresorbable scaffolds in percutaneous coronary interventions. Neth Heart J. 2015;23:153-60.
3. Caiazzo G, Kilic ID, Fabris E, Serdoz R, Mattesini A, Foin N, De Rosa S, Indolfi C, Di Mario C. Absorb bioresorbable vascular scaffold: What have we learned after 5 years of clinical experience? Int J Cardiol. 2015;201:129-36.
4. Kraak RP, Grundeken MJ, Koch KT, de Winter RJ, Wykrzykowska JJ. Bioresorbable scaffolds for the treatment of coronary artery disease: current status and future perspective. Expert Rev Med Devices. 2014;11:467-80.
5. Gogas BD. Bioresorbable scaffolds for percutaneous coronary interventions. Glob Cardiol Sci Pract. 2014;4:409-27.
6. Byrne RA, Serruys PW, Baumbach A, Escaned J, Fajadet J, James S, Joner M, Oktay S, Juni P, Kastrati A, Sianos G, Stefanini GG, Wijns W, Windecker S. Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. Eur Heart J. 2015;36:2608-20.
7. Verheye S, Ormiston JA, Stewart J, Webster M, Sanidas E, Costa R, Costa JR Jr, Chamie D, Abizaid AS, Pinto I, Morrison L, Toyloy S, Bhat V, Yan J, Abizaid A. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6-and 12-month clinical and multimodality imaging results. JACC Cardiovasc Interv. 2014;7:89-99.
8. Wiebe J, Nef HM, Hamm CW. Current status of bioresorbable scaffolds in the treatment of coronary artery disease. J Am Coll Cardiol. 2014;64:2541-51.
9. Diletti R, Karanasos A, Muramatsu T, Nakatani S, Van Mieghem NM, Onuma Y, Nauta ST, Ishibashi Y, Lenzen MJ, Ligthart J, Schultz C, Regar E, de Jaegere PP, Serruys PW, Zijlstra F, van Geuns RJ. Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study. Eur Heart J. 2014;35:777-86.
10. Kajiya T, Liang M, Sharma RK, Lee CH, Chan MY, Tay E, Chan KH, Tan HC, Low AF. Everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in patients with ST-segment elevation myocardial infarction (STEMI). EuroIntervention. 2013;9:501-4.
11. Zeller T, Rastan A, Macharzina R, Beschorner U, Noory E. Novel Approaches to the Management of Advanced Peripheral Artery Disease: Perspectives on Drug-Coated Balloons, Drug-Eluting Stents, and Bioresorbable Scaffolds. Curr Cardiol Rep. 2015;17:624.
12. Gori T, Wiebe J, Capodanno D, Latib A, Lesiak M, Pyxaras SA, Mehilli J, Caramanno G, Di Mario C, Brugaletta S, Weber J, Capranzano P, Sabate M, Mattesini A, Geraci S, Naber CK, Araszkiewicz A, Colombo A, Tamburino C, Nef H, Münzel T. Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: insights from the GHOST-EU registry. EuroIntervention. 2015 Sep 8;11. [Epub ahead of print].
13. Gomez-Lara J, Brugaletta S, Farooq V, van Geuns RJ, De Bruyne B, Windecker S, McClean D, Thuesen L, Dudek D, Koolen J, Whitbourn R, Smits PC, Chevalier B, Morel MA, Dorange C, Veldhof S, Rapoza R, Garcia-Garcia HM, Ormiston JA, Serruys PW. Angiographic geometric changes of the lumen arterial wall after bioresorbable vascular scaffolds and metallic platform stents at 1-year follow-up. JACC Cardiovasc Interv. 2011;4:789-99.
14. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
15. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.2. (2009). Chichester, UK: John Wiley and Sons Ltd.; 2010.
16. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive meta-analysis version 2. Englewood, NJ: Biostat 2005;104.
17. Cortese B, Ielasi A, Romagnoli E, Varricchio A, Cuculo A, Loi B, Pisano F, Corrado D, Sesana M, La Vecchia L, Summaria F, Tespili M, Silva Orrego P, Tognoni G, Steffenino G. Clinical Comparison With Short-Term Follow-Up of Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Stent in Primary Percutaneous Coronary Interventions. Am J Cardiol. 2015;116:705-10.
18. Costopoulos C, Latib A, Naganuma T, Miyazaki T, Sato K, Figini F, Sticchi A, Carlino M, Chieffo A, Montorfano M, Colombo A. Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population. Catheter Cardiovasc Interv. 2015;85:E10-5.
19. Puricel S, Arroyo D, Corpataux N, Baeriswyl G, Lehmann S, Kallinikou Z, Muller O, Allard L, Stauffer JC, Togni M, Goy JJ, Cook S. Comparison of everolimus-and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. J Am Coll Cardiol. 2015;65:791-801.
20. Serruys PW, Chevalier B, Dudek D, Cequier A, Carrie D, Iniguez A, Dominici M, van der Schaaf RJ, Haude M, Wasungu L, Veldhof S, Peng L, Staehr P, Grundeken MJ, Ishibashi Y, Garcia-Garcia HM, Onuma Y. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015;385:43-54.
21. Gori T, Schulz E, Hink U, Wenzel P, Post F, Jabs A, Münzel T. Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes. EuroIntervention. 2014;9:1036-41.
22. Brugaletta S, Gori T, Low AF, Tousek P, Pinar E, Gomez-Lara J, Scalone G, Schulz E, Chan MY, Kocka V, Hurtado J, Gomez-Hospital JA, Münzel T, Lee CH, Cequier A, Valdés M, Widimsky P, Serruys PW, Sabaté M. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction). JACC Cardiovasc Interv. 2015;8:189-97.
23. Kimura T, Kozuma K, Tanabe K, Nakamura S, Yamane M, Muramatsu T, Saito S, Yajima J, Hagiwara N, Mitsudo K, Popma JJ, Serruys PW, Onuma Y, Ying S, Cao S, Staehr P, Cheong WF, Kusano H, Stone GW; ABSORB Japan Investigators. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J. 2015;36:3332-42.
24. Muramatsu T, Onuma Y, van Geuns RJ, Chevalier B, Patel TM, Seth A, Diletti R, García-García HM, Dorange CC, Veldhof S, Cheong WF, Ozaki Y, Whitbourn R, Bartorelli A, Stone GW, Abizaid A, Serruys PW; ABSORB Cohort B Investigators; ABSORB EXTEND Investigators; SPIRIT FIRST Investigators; SPIRIT II Investigators; SPIRIT III Investigators; SPIRIT IV Investigators. 1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: a pooled analysis of the ABSORB and the SPIRIT trials. JACC Cardiovasc Interv. 2014;7:482-93.
25. Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, Popma JJ, McGreevy R, Zhang Z, Simonton C, Stone GW; ABSORB III Investigators. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. N Engl J Med. 2015;373:1905-15.
26. Gao R, Yang Y, Han Y, Huo Y, Chen J, Yu B, Su X, Li L, Kuo HC, Ying SW, Cheong WF, Zhang Y, Su X, Xu B, Popma JJ, Stone GW; ABSORB China Investigators. Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients with Coronary Artery Disease: ABSORB China trial. J Am Coll Cardiol. 2015;66:2298-309.
27. Sato K, Latib A, Panoulas VF, Kawamoto H, Naganuma T, Miyazaki T, Colombo A. Procedural feasibility and clinical outcomes in propensity-matched patients treated with bioresorbable scaffolds vs new-generation drug-eluting stents. Can J Cardiol. 2015;31:328-34.
28. Gross L, Sibbing D, Eickhoff M, Baquet M, Orban M, Grujic K, Krieg A, Theiss H, Brunner S, Teupser D, Holdt L, Massberg S, Mehilli J. Impact of the bioresorbable vascular scaffold surface area on on-treatment platelet reactivity. Platelets. 2016 Mar 4:1-6. [Epub ahead of print].
29. Cassese S, Byrne RA, Ndrepepa G, Kufner S, Wiebe J, Repp J, Schunkert H, Fusaro M, Kimura T. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials. Lancet. 2016;387:537-44.
30. Sabate M, Windecker S, Iniguez A, Okkels-Jensen L, Cequier A, Brugaletta S, Hofma SH, Raber L, Christiansen EH, Suttorp M, Pilgrim T, Anne van Es G, Sotomi Y, Garcia-Garcia HM, Onuma Y, Serruys PW. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarc-tion-TROFI II trial. Eur Heart J. 2016;37:229-40.
31. Zhang Y, Bourantas CV, Farooq V, Muramatsu T, Diletti R, Onuma Y, Garcia-Garcia HM, Serruys PW. Bioresorbable scaffolds in the treatment of coronary artery disease. Med Dev (Auckl). 2013;6:37-48.
32. Karanasos A, Van Meghem N, van Ditzhuijzen N, Felix C, Daemen J, Autar A, Onuma Y, Kurata M, Diletti R, Valgimigli M, Kauer F, van Beusekom H, de Jaegere P, Zijlstra F, van Geuns RJ, Regar E. Angiographic and optical coherence tomography insights into bioresorbable scaffold thrombosis single-center experience. Circ Cardiovasc Interv. 2015;8:e002369.
33. Cuculi F, Puricel S, Jamshidi P, Valentin J, Kallinikou Z, Toggweiler S, Weissner M, Münzel T, Cook S, Gori T. Optical Coherence Tomography Findings in Bioresorbable Vascular Scaffolds Thrombosis. Circ Cardiovasc Interv. 2015;8:e002518.
34. Puricel S, Cuculi F, Weissner M, Schmermund A, Jamshidi P, Nyffenegger T, Binder H, Eggebrecht H, Münzel T, Cook S, Gori T. Bioresorbable Coronary Scaffold Thrombosis: Multicenter Comprehensive Analysis of Clinical Presentation, Mechanisms, and Predictors. J Am Coll Cardiol. 2016;67:921-31.
35. ISAR-Absorb MI trial. https://clinicaltrials.gov/ct2/show/NCT01942070.
36. Albuquerque FN, Bortnick A, Iqbal J, Ishibashi Y, Stone GW, Serruys PW. Dual antiplatelet therapy, drug-eluting stents and bioresorbable vascular scaffolds: Evolutionary perspectives. Catheter Cardiovasc Interv. 2015 Aug 10. [Epub ahead of print].
37. Toušek P, Kocka V, Malý M, Lisa L, Budešínský T, Widimský P. Neointimal coverage and late apposition of everolimus-eluting bioresorbable scaffolds implanted in the acute phase of myocardial infarction: OCT data from the PRAGUE-19 study. Heart Vessels. 2015 Apr 21. [Epub ahead of print].
38. Barbato E, Wijns W. Bioresorbable coronary scaffolds: a novel device-based solution in search of its clinical need. Eur Heart J. 2014;35:753-7.